Labcorp announced its acquisition of MLM Medical Labs in a deal aimed at expanding its capabilities in central laboratories and biomarker testing for clinical trials. The two companies did not disclose the financial terms of the agreement.
MLM operates laboratories and facilities in the United States, Germany and South Africa. Its facilities include laboratories in Memphis and Mönchengladbach, as well as its subsidiary, Cytespace Africa Laboratories, in South Africa. According to Labcorp, the deal makes it the only central laboratory provider with a wholly owned laboratory network spanning four continents.
Additional Capabilities for Complex Trial Programs
MLM develops laboratory tests customized for facilities and validates them to support specialized clinical and translational research. Labcorp also pointed to the acquired company’s scientific and regulatory expertise, along with its biomarker and specialized testing capabilities, as important factors in supporting complex clinical trial programs.
These capabilities intersect with the central laboratory infrastructure Labcorp has built through previous deals, including its $6.1 billion acquisition of Covance. However, the MLM deal differs from much of Labcorp’s acquisition activity in recent years, which has focused more heavily on buying regional laboratory assets to expand its presence within the United States.
What Is Changing in Practice?
The deal adds to Labcorp a geographically distributed operating network serving clinical trial sponsors, rather than limiting expansion to local laboratory services. The company says the network includes North America, Europe, Asia and Africa, while MLM’s announced operations include laboratories in the United States, Germany and South Africa. Labcorp also said that MLM operates Africa’s first fully College of American Pathologists (CAP)-accredited central laboratory.
MLM expanded in recent years through a series of acquisitions. It acquired the Memphis site in 2020 in a deal involving CirQuest Labs, added further U.S. capacity by purchasing MD Biosciences that same year, and then acquired Cytespace last year to strengthen its capabilities in Africa.
Significance and Limitations of the Deal
The deal comes as Labcorp’s central laboratory services sales grew 9.8% year over year during the second quarter, contributing to the company raising its full-year sales outlook for its biopharmaceutical laboratory services unit. Labcorp also spent $528.6 million, net of cash acquired, on acquisitions during the first half of 2026, and agreed in late June to pay an additional $155 million for selected assets from a referral laboratory services business.
The key takeaway is that part of Labcorp’s strategy is shifting from strengthening its local footprint to building a wholly owned global capability serving clinical trials. However, the available information does not clarify the operational integration details or the deal’s impact on customers and pricing, and its financial value has not been disclosed; therefore, measuring its actual return on the clinical trial business remains open.